한글목차

EXPAREL(부피바카인 리포솜 주사용 현탁액)은 성인의 수술 후 국소 진통을 목적으로 한 단회 침윤 및 수술 후 국소 진통을 목적으로 한 쇄골간완 신경총 신경 블록을 적응으로 하고 있습니다. 신경 블록의 안전성과 효능은 확립되어 있지 않습니다. 사이에 전달하는 입증된 제품 전달 기술입니다. EXPAREL은 수술 전후에 사용 가능한 다포막 리포솜 국소 마취제입니다. 누적 통증 점수의 상당한 감소를 가져오고 오피오이드 소비를 최대 78% 감소시킵니다.

앞으로 몇 년동안 세계의 광범위한 조사와 의료비 증가로 수술 후 통증 시장 시나리오가 변할 것입니다. 개발, 과제 평가, EXPAREL의 이점에 영향을 미칩니다. 수술 후 통증을 대상으로 한 다른 신흥 제품도 EXPAREL과 엄격한 시장 경쟁을 펼칠 것으로 예상되며, 가까운 미래에, 후발의 신흥 치료제이 상시되면, 시장에 큰 영향을 미칠 것으로 보입니다.

이 보고서는 주요 7개국의 EXPAREL 시장을 조사했으며,, 시장 개요와 함께 경쟁 구도, 2032년까지 시장 규모 예측, 국가별 시장 분석 등을 제공합니다.

목차

제1장 보고서 소개

제2장 수술 후 통증에 관한 EXPAREL 개요

• 제품 상세
• 임상 개발
• 규제 마일스톤
• 기타 개발 활동
• 제품 프로파일

제3장 경쟁 구도(출시된 치료법

제4장 경쟁 구도(후기 단계의 신흥 치료법

제5장 EXPAREL 시장 평가

• 수술 후 통증에 대한 EXPAREL 시장 전망
• 주요 7개국 분석
• 국가별 시장 분석
  • 미국
  • 독일
  • 영국

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight 정보

제12장 보고서 구매 옵션

영문목차

"EXPAREL Market Size, Forecast, and Market Insight - 2032" report provides comprehensive insights about EXPAREL for Postoperative pain in the seven major markets. A detailed picture of the EXPAREL for Postoperative pain in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the EXPAREL for Postoperative pain. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the EXPAREL market forecast analysis for Postoperative pain in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Postoperative pain.

Drug Summary:

EXPAREL (bupivacaine liposome injectable suspension) is indicated for single-dose infiltration in adults to produce postsurgical local analgesia and as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia. Safety and efficacy have not been established in other nerve blocks. The product combines bupivacaine with DepoFoam, a proven product delivery technology that delivers medication over a desired period. EXPAREL represents the multivesicular liposome local anesthetic that can be utilized in the peri- or postsurgical setting. By utilizing the DepoFoam platform, a single dose of EXPAREL delivers bupivacaine over time, providing significant reductions in cumulative pain scores with up to a 78% decrease in opioid consumption; the clinical benefit of the opioid reduction was not demonstrated.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the EXPAREL description, mechanism of action, dosage and administration, research and development activities in Postoperative pain.
• Elaborated details on EXPAREL regulatory milestones and other development activities have been provided in this report.
• The report also highlights the EXPAREL research and development activities in Postoperative pain across the United States, Europe, and Japan.
• The report also covers the patents information with expiry timeline around EXPAREL.
• The report contains forecasted sales of EXPAREL for Postoperative pain till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Postoperative pain.
• The report also features the SWOT analysis with analyst views for EXPAREL in Postoperative pain.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

EXPAREL Analytical Perspective by DelveInsight

• In-depth EXPAREL Market Assessment

This report provides a detailed market assessment of EXPAREL for Postoperative pain in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

• EXPAREL Clinical Assessment

The report provides the clinical trials information of EXPAREL for Postoperative pain covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Postoperative pain is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence EXPAREL dominance.
• Other emerging products for Postoperative pain are expected to give tough market competition to EXPAREL and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of EXPAREL in Postoperative pain.
• Our in-depth analysis of the forecasted sales data of EXPAREL from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the EXPAREL in Postoperative pain.

Key Questions:

• What is the product type, route of administration and mechanism of action of EXPAREL?
• What is the clinical trial status of the study related to EXPAREL in Postoperative pain and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the EXPAREL development?
• What are the key designations that have been granted to EXPAREL for Postoperative pain?
• What is the forecasted market scenario of EXPAREL for Postoperative pain?
• What are the forecasted sales of EXPAREL in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to EXPAREL for Postoperative pain?
• Which are the late-stage emerging therapies under development for the treatment of Postoperative pain?

Table of Contents

1. Report Introduction

2. EXPAREL Overview in Postoperative pain

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Regulatory Milestones
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. EXPAREL Market Assessment

• 5.1. Market Outlook of EXPAREL in Postoperative pain
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of EXPAREL in the 7MM for Postoperative pain
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of EXPAREL in the United States for Postoperative pain
  • 5.3.2. Market Size of EXPAREL in Germany for Postoperative pain
  • 5.3.3. Market Size of EXPAREL in France for Postoperative pain
  • 5.3.4. Market Size of EXPAREL in Italy for Postoperative pain
  • 5.3.5. Market Size of EXPAREL in Spain for Postoperative pain
  • 5.3.6. Market Size of EXPAREL in the United Kingdom for Postoperative pain
  • 5.3.7. Market Size of EXPAREL in Japan for Postoperative pain

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options